Changes in therapeutic strategy in metastatic castration resistant prostate cancer between 2012 and 2014 from the French nationwide claims database

被引：0
|
作者：
Thurin, Nicolas H. [1 ]
Rouyer, Magali [1 ]
Jove, Jeremy [1 ]
Gross-Goupil, Marine [2 ]
Haaser, Thibaud [2 ]
Rebillard, Xavier [3 ]
Soulie, Michel [4 ]
de Pouvourville, Gerard [5 ]
Capone, Camille [6 ]
Pierres, Marie [6 ]
Lamarque, Stephanie [1 ]
Bignon, Emmanuelle [1 ]
Droz-Perroteau, Cecile [1 ]
Moore, Nicholas [1 ,2 ]
Blin, Patrick [1 ]
机构：
[1] Univ Bordeaux, Bordeaux PharmacoEpi, INSERM, CIC1401, Bordeaux, France
[2] CHU Bordeaux, Bordeaux, France
[3] Clin Beau Soleil, Montpellier, France
[4] CHU Toulouse, Toulouse, France
[5] ESSEC, Cergy Pontoise, France
[6] Janssen, Issy Les Moulineaux, France
来源：
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY | 2020年 / 29卷
关键词：
D O I：
暂无
中图分类号：
R1 [预防医学、卫生学];
学科分类号：
1004 ; 120402 ;
摘要：
4343
引用
收藏
页码：250 / 250
页数：1
相关论文
共 50 条
  • [31] CORRELATION BETWEEN CABAZITAXEL RESISTANCE AND EMT IN METASTATIC CASTRATION RESISTANT PROSTATE CANCER
    Hongo, Hiroshi
    Kosaka, Takeo
    Yasumizu, Yota
    Miyazaki, Yasumasa
    Kikuchi, Eiji
    Miyajima, Akira
    Oya, Mototsugu
    JOURNAL OF UROLOGY, 2017, 197 (04): : E1109 - E1109
  • [32] Identification of patients with metastatic castration-sensitive or metastatic castration-resistant prostate cancer using administrative health claims and laboratory data
    Freedland, Stephen J.
    Ke, Xuehua
    Lafeuille, Marie-Helene
    Romdhani, Hela
    Kinkead, Frederic
    Lefebvre, Patrick
    Petrilla, Allison
    Pulungan, Zul
    Kim, Seung
    D'Andrea, Denise M.
    Francis, Peter
    Ryan, Charles J.
    CURRENT MEDICAL RESEARCH AND OPINION, 2021, 37 (04) : 609 - 622
  • [33] Association Between RECIST Changes and Survival in Patients with Metastatic Castration-resistant Prostate Cancer Receiving Docetaxel
    Sonpavde, Guru
    Pond, Gregory R.
    Templeton, Arnoud J.
    Fandi, Abderrahim
    Tombal, Bertrand
    Rosenthal, Mark
    Armstrong, Andrew J.
    Petrylak, Daniel P.
    EUROPEAN UROLOGY, 2016, 69 (06) : 980 - 983
  • [34] Metastatic castration-resistant prostate cancer and PARP inhibitors: From tumor genomics to new therapeutic combinations
    Oudard, Stephane
    Timsit, Marc-Olivier
    Maillet, Denis
    Mouillet, Guillaume
    Campedel, Luca
    Colomba, Emeline
    Dourthe, Louis Marie
    Eymard, Jean-Christophe
    Gobert, Aurelien
    Jamet, Claire
    Joly, Charlotte
    Serrate, Camille
    Ploussard, Guillaume
    BULLETIN DU CANCER, 2025, 112 (01) : 61 - 81
  • [35] PSMA radioligand therapy rechallenging: expanding the therapeutic possibilities in metastatic castration resistant prostate cancer
    Volpe, Fabio
    Piscopo, Leandra
    Klain, Michele
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2024, 51 (13) : 4163 - 4164
  • [36] Therapeutic vaccines in metastatic castration-resistant prostate cancer: principles in clinical trial design
    Madan, Ravi A.
    Mohebtash, Mahsa
    Schlom, Jeffrey
    Gulley, James L.
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2010, 10 (01) : 19 - 28
  • [37] Beyond PSA: Managing Modern Therapeutic Options in Metastatic Castration-Resistant Prostate Cancer
    Karzai, Fatima H.
    Madan, Ravi A.
    Figg, William D.
    SOUTHERN MEDICAL JOURNAL, 2015, 108 (04) : 224 - 228
  • [38] Relationship between Circulating Lipids and Cytokines in Metastatic Castration-Resistant Prostate Cancer
    Lin, Hui-Ming
    Yeung, Nicole
    Hastings, Jordan F.
    Croucher, David R.
    Huynh, Kevin
    Meikle, Thomas G.
    Mellett, Natalie A.
    Kwan, Edmond M.
    Davis, Ian D.
    Tran, Ben
    Mahon, Kate L.
    Zhang, Alison
    Stockler, Martin R.
    Briscoe, Karen
    Marx, Gavin
    Bastick, Patricia
    Crumbaker, Megan L.
    Joshua, Anthony M.
    Azad, Arun A.
    Meikle, Peter J.
    Horvath, Lisa G.
    CANCERS, 2021, 13 (19)
  • [39] Validation of correlation of RECIST changes with survival in metastatic castration-resistant prostate cancer (mCRPC).
    Pond, Gregory Russell
    Templeton, Arnoud J.
    Petrylak, Daniel Peter
    Fandi, Abderrahim
    Tombal, Bertrand F.
    Rosenthal, Mark
    Sonpavde, Guru
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [40] Safety profile of abiraterone and enzalutamide in the castration-resistant prostate cancer, according to the French Pharmacovigilance database
    Scailteux, L. M.
    Despas, F.
    Bellissant, E.
    Oger, E.
    Polard, E.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2021, 35 : 126 - 126
12345